Eli Lilly and Company has become a key player in the production of tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant potential to improve glycemic control and reduce heart disease. The complex manufacturing process of tirzepatide involves a series of meticulous proc